Opinion|Videos|August 7, 2024
AYA ALL: Role of Asparaginase Erwinia Chrysanthemi
Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.
Advertisement
Video content above is prompted by the following questions:
- Please comment on the trial led to the approval of use for asparaginase erwinia chrysanthemi in AYA ALL.
- How does for asparaginase erwinia chrysanthemi work?
- What are your thoughts on the key efficacy outcomes?
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Advertisement
Advertisement
Trending on OncLive
1
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
5